185P Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)
Makaleler > Tam Makale · 2024
Yazarlar: C. Anders, S. Loi, E.P. Hamilton, K. Jhaveri, P. Schmid, Erhan GÖKMEN, S-A. Im, C. Karacin, C.H. Barrios, Y.H. Park, S. Uzunoglu, S. Boston, A. Konpa, S. Mondal, F. André
ESMO Open, Uluslararası, Wos, 2024, cilt 9, ss 103207-103207
DOI: 10.1016/j.esmoop.2024.103207
Özet
DEBBRAH, ROSET-BM, TUXEDO-1, and a pooled DB-01, -02, -03 analysis indicate robust efficacy of T-DXd in pts with stable/active BM; however, efficacy in pts with BM is not yet fully established. DB-07 is a phase Ib/II, multicenter, open-label study exploring the safety, tolerability, and antitumor activity of T-DXd alone or in combination with other anticancer agents (NCT04538742). Results are from an interim analysis of the dose-expansion phase of T-DXd monotherapy in pts with active BM.